AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01080235 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ABIM Care of Vulnerable Elderly Practice Improvement Module
Description: The ABIM CoVE PIM is a practice-performance self-evaluation instrument. It is a web-based tool based on nationally recognized guidelines that uses chart abstraction, patient surveys, and a practice system survey in order to generate a performance report focused on a key aspects of care for vulnerable elderly.
Study NCT01080235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Geriatric and Quality Improvement toolkit
Description: A resource toolkit about geriatrics and quality improvement was given to both study arms.
Study NCT01080235 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Geriatric and Quality Improvement toolkit
Description: A resource toolkit about geriatrics and quality improvement was given to both study arms.
Study NCT00541424 — intervention group
Intervention type: PROCEDURE
Intervention: PET/CT Scanning
Description: Full-body PET/CT procedure will be performed. Gas will be pumped into the colon before the scan so the colon will be opened up (inflated) and the study doctor will be able to more easily look for any lesions. This procedure is called gas insufflation.
Study NCT03971123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to AC-SD-03 50g of AC-SD-03P mixed in 240mL dosing liquid at Hour 0 Day 1
Study NCT02784587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, which typically requires about 3 minutes to perform. The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 (Chassaignac's tubercle) or C7 (3-5 cm above the clavicle). The non-operative hand will retract the muscle together with the carotid sheath prior to needle insertion. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
Study NCT00071032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liberal (10 g/dL) Transfusion Strategy
Description: This transfusion strategy will maintains postoperative Hgb levels above 10 g/dL. This threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.
Study NCT00071032 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive (Symptomatic) Transfusion Strategy
Description: Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL. Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.
Study NCT02903147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Meta-Cognitive Intervention
Description: Functional-Meta-Cognitive Intervention Program was focused on raising awareness to safe driving risk factors identified at pre-screening, with reference to the difficulties that the driver raises and providing coping strategies. The intervention has been customized for each driver and included three sessions of two hours.
Study NCT02903147 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The employer's training
Study NCT04172220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 1-2 mg of Midazolam as premedication.
Study NCT04172220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 1-2 mg of Midazolam as premedication.
Study NCT04172220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS
Description: Loco-regional anesthesia: PEC I and serratus plane block with an echoguided technique.~For the PEC I: infiltration of 10 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of the pectoralis major muscle and the small pectoralis muscle at the height of the third rib on the anterior axillary line.~For the serratus plane block: identification of the fifth rib on the average axillary line and infusion of about 20 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of large dorsal muscle and of the anterior serratus muscle.
Study NCT04172220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioid-free general anesthesia
Description: Induction with Propofol 1.5-2 mg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in Target-Controlled Infusion (TCI) of 6 mcg/ml, subsequently modified to maintain a Bispectral Index (BIS) value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase >20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer.
Study NCT04172220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Induction with Propofol 1.5-2 mg/kg; Fentanyl 1μg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in TCI of 6 mcg/ml, subsequently modified to maintain a BIS value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase >20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer.
Study NCT04172220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia
Description: Paracetamol 1000 mg every 8 hours for the first 24 hours, Ketorolac 30 mg in case of pain control failure (Numeric Rating Scale- NRS>4) which can be administered every 8 hours at most (max 90 mg / 24 hours), Morphine 10-20 mg IV in 24 hours as rescue analgesia.
Study NCT04172220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative analgesia
Description: Paracetamol 1000 mg every 8 hours for the first 24 hours, Ketorolac 30 mg in case of pain control failure (Numeric Rating Scale- NRS>4) which can be administered every 8 hours at most (max 90 mg / 24 hours), Morphine 10-20 mg IV in 24 hours as rescue analgesia.
Study NCT03971123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricaprilin
Description: Tricaprilin formulated as AC-1202 60g of AC-1202 (20g caprlic triglyceride) mixed in 240mL dosing liquid at Hour 0 Day 1
Study NCT04339686 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thoracic CT Scan
Description: Retrospective analysis of the thoracic CT scan results compared to final discharge summary
Study NCT03172819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OBP-301
Description: Intratumoral injection directly into the dose target region of a tumor at Day 1, Day 15, and Day 29.~Additional administration of OBP-301 After the recommended dose of OBP-301 has been established, additional administration of OBP-301 is allowed. After completion of administration of OBP-301 on Day 1 - Day 29(+/- 4 days), if the target region has not disappeared, additional administration of OBP-301 is allowed after Day 43 or later.~The patients in Phase 1a, Pembrolizumab administration has continued, are included.~The recommended dose determined in the Phase 1a part will be administered 3 times biweekly (+/- 4 days); max 4 cycles.
Study NCT03172819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Pembrolizumab is infused intravenously at Day 8. Thereafter infusion will continue every 3 weeks until discontinuation.
Study NCT01275300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT02956070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Description: The volunteers in the Dexamethasone acetate group (experimental group) will receive six capsules of dexamethasone 8 mg each to be administered orally, initially two days before the first bleaching query as follows: 8 mg (1 capsule) 9 am two days before the first clinical session whitening; 8 mg (1 capsule) the 9 am to 1 day before session whitening, 8 mg (1 capsule) to 9 am on the day of the first session of whitening.Clinical intervention: 1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A placebo gel will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
Study NCT02956070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium Nitrate
Description: The volunteers in the Potassium Nitrate Group (Placebo group) will receive 6 placebo capsules, who contained the same components of de dexamethasone drug except the active ingredient (starch \[50%\], lactose monohydrate \[35%\], dibasic calcium phosphate \[14%\], and magnesium stearate \[1%\]).Clinical session:1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A desensitizing gel containing 6% potassium nitrate will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
Study NCT01275300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01275300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Study NCT01275300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niacin
Study NCT02215473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate mouth rinse
Description: Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
Study NCT02215473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal instrumentation
Description: Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
Study NCT02215473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal instrumentation
Description: Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
Study NCT02971163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SynDA
Description: SynDA is a paper-based, personalized decision aid which gives information to patients about their medical condition (i.e. syncope), future risk, and options for care. It is written in lay language and aims to create an informed conversation between a patient and their ED provider.
Study NCT03648892 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [c11] raclopride
Description: The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
Study NCT03648892 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [18F]fallypride
Description: The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
Study NCT04573738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic assisted transanal total mesorectal excision
Description: Robotic assisted transanal total mesorectal excision for rectal cancer patients
Study NCT04573738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic assisted transanal total mesorectal excision
Description: Laparoscopic assisted transanal total mesorectal excision for rectal cancer patients
Study NCT00802906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: subthreshold micropulselaser
Description: on demand if leakage is persistent or recurs after initial treatment
Study NCT00802906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 1.5 mg initial intravitreal injection
Study NCT00539500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin by vein over 24 hours for 4 days, dosing as determined at day 1.
Study NCT00539500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 300 mg/m\^2 by vein over 24 hours for 4 days
Study NCT00539500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2 Intravenous Bolus for 3 Days
Study NCT00539500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem Cell Infusion (approximately 5x10\^8 TNC cells/kg CD133+ selected) on Day 0.
Study NCT00539500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClinicMACS
Description: Device used to process the blood and separate the CD 133+ cells needed for transplantation
Study NCT03716193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Patients will be given oxygen via a facemask during the measurement session
Study NCT04100018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT04100018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Specified dose on specified days
Study NCT04100018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Specified dose on specified days
Study NCT04100018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days
Study NCT04100018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Specified dose on specified days
Study NCT04100018 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT00748605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-2367 Placebo
Description: Four placebo tablets (total dose = 0 mg/day S-2367) administered orally once daily with AM (ante meridiem) meal while on both LCD (low calorie diet for 6 weeks) and RCD (reduced calorie diet for 54 weeks) for a total of 60 weeks
Study NCT00748605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-2367 Placebo
Description: Four placebo tablets (total dose = 0 mg/day S-2367) administered orally once daily with AM (ante meridiem) meal while on both LCD (low calorie diet for 6 weeks) and RCD (reduced calorie diet for 54 weeks) for a total of 60 weeks
Study NCT00748605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-2367 1600 mg q.d. 54 Weeks
Description: Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on RCD for a total of 54 weeks
Study NCT00748605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-2367 1600 mg q.d. 60 weeks
Description: Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on both LCD and RCD for a total of 60 weeks
Study NCT00748605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LCD (low calorie diet)
Description: A low calorie diet was utilized during the first 6 weeks of the study
Study NCT00748605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCD (low calorie diet)
Description: A low calorie diet was utilized during the first 6 weeks of the study
Study NCT00748605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RCD (reduced calorie diet)
Description: A reduced calorie diet was used during the last 54 weeks for the study
Study NCT00748605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RCD (reduced calorie diet)
Description: A reduced calorie diet was used during the last 54 weeks for the study
Study NCT03477565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape lymphatic drainage technique application
Description: Kinesio Tex Tape strips are applied following Dr.Kase draining techinique. The choice of tape's length and strips' number is based on the area of breast edema and/or presence of seroma, which must be completely covered. The patch is cut into fan strips. The major base is positioned near the functioning lymph node stations closest to the edema and/or seroma area. The bases and the tails of the fan must be applied with zero tension, while for the central part is reached 15-25% of tension. The first application takes place on the 1st post-operative day, while the second is performed on the 7th post-operative day. In case the tape is detached from one application to another, it is necessary that the patient resume in the clinic for a new application to ensure continuity of the therapeutic effect; otherwise the patient is eliminated from the study. The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and counselin.
Study NCT03013491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-072
Study NCT03828526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fidelity Simulation
Description: Teaching strategy based on high fidelity simulation, which simulates the reality of health care to promote meaningful learning.
Study NCT03828526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional teaching strategy
Description: Classroom-based strategy
Study NCT00751985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalised normative feedback (PNF)
Description: The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The brief personalised normative feedback will comprise the result of the participant's amount of alcohol consumption, previously given in an online questionnaire.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. The feedback is also comparing their drinking, in graphical format, to the average drinking in the municipality concerned. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help.
Study NCT00751985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help material
Description: The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The intervention comprises of on-line self-help material informing about the participant's response from an online questionnaire shows that the participant's alcohol consumption exceeds the recommended limits.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help.
Study NCT00751985 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The participant is being informed about their allocation to the control group.
Study NCT00980798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone HCl
Description: 4 to 32 mg taken orally once daily for 16 weeks
Study NCT00980798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet once daily for 16 weeks
Study NCT00631917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Aliskiren
Description: Placebo tablets to match aliskiren.
Study NCT01208467 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02651831 — intervention group
Intervention type: OTHER
Intervention: Focus groups and individual interviews
Description: Focus groups conducted to explore general experiences, insights and concerns of those receiving ICM therapies. Individual semi-structured interviews to provide in-depth data on the themes identified in the focus groups.
Study NCT02651831 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Health related quality of life questionnaire (FACT-ICM) to be completed by patients
Study NCT03334591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg with Docetaxel 60mg/m2
Study NCT00145535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOLX Titanium Sapphire Laser (TiSaLT)
Description: Spot laser treatment, \~50 spots over 180°
Study NCT00145535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Laser Trabeculoplasty (ALT)
Description: Spot laser treatment, \~50 spots over 180°